Bayesian Capital Management LP Makes New Investment in Definitive Healthcare Corp. (NASDAQ:DH)

Bayesian Capital Management LP acquired a new stake in shares of Definitive Healthcare Corp. (NASDAQ:DH) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 10,046 shares of the company’s stock, valued at approximately $41,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in DH. Nisa Investment Advisors LLC lifted its position in Definitive Healthcare by 3,652.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 6,980 shares of the company’s stock worth $29,000 after buying an additional 6,794 shares during the period. Ieq Capital LLC acquired a new stake in shares of Definitive Healthcare in the fourth quarter worth approximately $51,000. KLP Kapitalforvaltning AS purchased a new stake in Definitive Healthcare in the fourth quarter valued at approximately $54,000. Two Sigma Securities LLC acquired a new position in Definitive Healthcare during the fourth quarter worth approximately $56,000. Finally, Quantbot Technologies LP raised its stake in Definitive Healthcare by 5,305.5% during the fourth quarter. Quantbot Technologies LP now owns 17,730 shares of the company’s stock worth $73,000 after purchasing an additional 17,402 shares during the period. 98.67% of the stock is currently owned by hedge funds and other institutional investors.

Definitive Healthcare Trading Up 31.3 %

Shares of DH opened at $3.69 on Friday. Definitive Healthcare Corp. has a one year low of $2.15 and a one year high of $6.27. The stock has a 50-day moving average price of $2.71 and a 200 day moving average price of $3.87. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.49 and a current ratio of 2.49. The company has a market capitalization of $398.38 million, a P/E ratio of -1.19, a P/E/G ratio of 4.06 and a beta of 1.48.

Definitive Healthcare (NASDAQ:DH) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.02 by $0.03. The business had revenue of $59.19 million for the quarter, compared to analysts’ expectations of $56.20 million. Definitive Healthcare had a negative net margin of 142.38% and a positive return on equity of 1.76%. The company’s quarterly revenue was down 6.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.08 earnings per share. Sell-side analysts forecast that Definitive Healthcare Corp. will post 0.16 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. BTIG Research downgraded Definitive Healthcare from a “buy” rating to a “neutral” rating in a report on Friday. The Goldman Sachs Group cut their price objective on Definitive Healthcare from $4.50 to $3.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Barclays dropped their target price on shares of Definitive Healthcare from $4.00 to $3.00 and set an “underweight” rating for the company in a research report on Monday, March 3rd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Definitive Healthcare in a research report on Thursday, January 16th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $5.06.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.